Screener
Jade Biosciences JBIO Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Jade Biosciences in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:27 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-212088
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Net loss | $(40,368) | $(38,169) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Change in fair value of Convertible Notes payable | — | 15,400 |
| Stock-based compensation | 7,405 | 2,423 |
| Non-cash lease expense | 26 | 8 |
| Accretion/amortization on investments | (493) | — |
| Depreciation expense | 9 | — |
| Changes in operating assets and liabilities: |
Item 1. Financial Statements.
FAQ
- What is Jade Biosciences's stock-based comp?
- Jade Biosciences (JBIO) reported stock-based comp of $7.41M in Q1 2026.
- How has Jade Biosciences's stock-based comp changed year-over-year?
- Jade Biosciences's stock-based comp increased by 205.6% year-over-year, from $2.42M to $7.41M.
- What is the long-term trend for Jade Biosciences's stock-based comp?
- Over 4 years (2021 to 2025), Jade Biosciences's stock-based comp has grown at a 76.9% compound annual growth rate (CAGR), from $2.04M to $20.01M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.
Ask your AI about Jade Biosciences's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude